EUVIMEDEUVIMED entdecken
Crossref

Dipeptidyl peptidase‐4 inhibitor and sodium‐glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high‐fat diet‐fed mice

Yuichiro Iwamoto iD, Tomohiko Kimura iD, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda iD, Yuka Nogami, Yoshiko Shirakiya, Shuhei Nakanishi, Tomoatsu Mune und 2 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Yuichiro Iwamoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan. Hauptthemen laut MEDLINE: Diet, High-Fat, Dipeptidyl-Peptidase IV Inhibitors, Fatty Liver, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Kawasaki Medkical School, Taisho Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors suppress the inactivation of incretin hormones and lower blood glucose levels by inhibiting DPP‐4 function. Sodium‐glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels in an insulin‐independent manner by inhibiting renal reabsorption of glucose. DPP‐4 and SGLT2 inhibitors each have the potential to improve hepatic steatosis; however, their combined effects remain unclear. In this study, we examined the effects of the combination of these drugs on hepatic steatosis using high‐fat diet‐fed mice.

Method

C57BL/6J male mice were fed a 60% high‐fat diet for 2 months to induce hepatic steatosis. Mice were divided into four groups (control; DPP‐4 inhibitor anagliptin; SGLT2 inhibitor luseogliflozin; anagliptin and luseogliflozin combination), and the effects of each drug and their combination on hepatic steatosis after a 4‐week intervention were evaluated.

Results

There were no differences in blood glucose levels among the four groups. Anagliptin suppresses inflammation‐ and chemokine‐related gene expression. It also improved macrophage fractionation in the liver. Luseogliflozin reduced body weight, hepatic gluconeogenesis and blood glucose levels in the oral glucose tolerance test. The combination treatment improved hepatic steatosis without interfering with the effects of anagliptin and luseogliflozin, respectively, and fat content and inflammatory gene expression in the liver were significantly improved in the combination group compared with the other groups.

Conclusion

The combination therapy with the DPP‐4 inhibitor anagliptin and the SGLT2 inhibitor luseogliflozin inhibits fat deposition in the liver via anti‐inflammatory effects during the early phase of diet‐induced liver steatosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diet, High-FatDipeptidyl-Peptidase IV InhibitorsFatty LiverSodium-Glucose Transporter 2 InhibitorsAnimalsMaleMiceBlood GlucoseDrug SynergismDrug Therapy, CombinationGlucosidesLiverMice, Inbred C57BLNon-alcoholic Fatty Liver DiseasePyrimidinesSorbitol

Stichwörter der Autor:innen

diabetic therapydipeptidyl peptidase‐4 inhibitormetabolic dysfunction‐associated steatotic liver diseasemicesodium‐glucose cotransporter 2 inhibitor

Substanzen

1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitolanagliptinBlood GlucoseDipeptidyl-Peptidase IV InhibitorsGlucosidesPyrimidinesSodium-Glucose Transporter 2 InhibitorsSorbitol

Autor:innen und Institutionen

  • Department of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.

ORCID-Profile: Yuichiro Iwamoto, Tomohiko Kimura, Masashi Shimoda, Kohei Kaku

Förderung

  • Kawasaki Medkical School
  • Taisho Pharmaceutical Co., Ltd.

Zitieren

APA

Iwamoto, Y., Kimura, T., Dan, K., Iwamoto, H., Sanada, J., Fushimi, Y., Katakura, Y., Shimoda, M., Nogami, Y., Shirakiya, Y., Nakanishi, S., Mune, T., Kaku, K., & Kaneto, H. (2024). Dipeptidyl peptidase‐4 inhibitor and sodium‐glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high‐fat diet‐fed mice. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15548

Vancouver

Iwamoto Y, Kimura T, Dan K, Iwamoto H, Sanada J, Fushimi Y, et al. Dipeptidyl peptidase‐4 inhibitor and sodium‐glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high‐fat diet‐fed mice. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15548

BibTeX
@article{Iwamoto2024,
  author = {Iwamoto, Yuichiro and Kimura, Tomohiko and Dan, Kazunori and Iwamoto, Hideyuki and Sanada, Junpei and Fushimi, Yoshiro and Katakura, Yukino and Shimoda, Masashi and Nogami, Yuka and Shirakiya, Yoshiko and Nakanishi, Shuhei and Mune, Tomoatsu and Kaku, Kohei and Kaneto, Hideaki},
  title = {Dipeptidyl peptidase‐4 inhibitor and sodium‐glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high‐fat diet‐fed mice},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15548}
}
Kostenlos starten →